Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.48 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.48 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.48 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 4/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | RAB9A | P51151 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | HK1 | P19367 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | CDC25A | P30304 | 1/20 | 0.47 |
| ▸ | CDC25B | P30305 | 1/20 | 0.47 |
| ▸ | CDC25C | P30307 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL251773 | 0.87 | TSHR (0.67) | TP53TSHRMAPK13MAPK12MAPK11 | |
| SCHEMBL8727096 | 0.82 | ROCK1 (0.46) | TSHRMAPK13MAPK12MAPK11MAPK14 | |
| 4-Phenylamino Benzoic Acid SCHEMBL70190 | 0.80 | MAPK13 (0.72) | TP53TSHRMAPK13MAPK12MAPK11 | |
| SCHEMBL9479471 | 0.80 | MAPK13 (0.72) | TP53TSHRMAPK13MAPK12MAPK11 | |
| SCHEMBL5142231 | 0.80 | RHOA (0.61) | NPC1KMT2ARAB9AMAPTMEN1 | |
| SCHEMBL20583 | 0.79 | — | — | |
| SCHEMBL8070391 | 0.79 | TSHR (0.61) | TP53TSHRSMN1; SMN2SRD5A2ALDH1A1 | |
| SCHEMBL2127845 | 0.78 | TYR (0.73) | TP53TSHRMAPK13MAPK12MAPK11 | |
| SCHEMBL29124318 | 0.77 | TSHR (0.58) | TP53TSHRSMN1; SMN2SRD5A2ALDH1A1 | |
| SCHEMBL28987694 | 0.77 | TSHR (0.58) | TP53TSHRSMN1; SMN2SRD5A2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1423111-A4 | FXR NR1H4 NUCLEAR RECEPTOR BINDING COMPOUNDS | PHENEX PHARMACEUTICALS AG (DE) | 2007-04-18 | — | — | EP | disclosed |
| US-7034046-B2 | NR1H4 nuclear receptor binding compounds | PHENEX PHARMACEUTICALS AG (DE) | 2006-04-25 | — | — | US | disclosed |
| EP-1423111-A1 | FXR NR1H4 NUCLEAR RECEPTOR BINDING COMPOUNDS | LION Bioscience AG (DE) | 2004-06-02 | — | — | EP | disclosed |
| US-20030187042-A1 | NR1H4 nuclear receptor binding compounds | PHENEX PHARMACEUTICALS AG (DE) | 2003-10-02 | — | — | US | disclosed |
| WO-2003015771-A1 | FXR NR1H4 NUCLEAR RECEPTOR BINDING COMPOUNDS | LION BIOSCIENCE AG (DE) | 2003-02-27 | — | — | WO | disclosed |
| US-4040840-A | MEROCYANINE DYE HAVING ISOXAZOLE NUCLEUS AND PYRAZOLINE-5-ONE NUCLEUSN | FUJI PHOTO FILM CO., LTD. (JA) | 1977-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030187042-A1 | NR1H4 nuclear receptor binding compounds | NR1H4, NR1H2, NR1H3 | TP53 4636/4885TSHR 165/4885MAPK13 2608/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.